Worldwide Healthcare Trust PLC (WWH) has published unaudited results for the six months ended 30 September 2026, reporting a net asset value per share total return of +9.3% and a share price total return of +14.8% against a benchmark return of +9.9% from the MSCI World Health Care Index. The investment trust, which pursues active global healthcare equity investment across pharmaceuticals, biotechnology, medical technology and healthcare services, saw its discount to NAV narrow from 10.0% to 5.5% during the period. Investors will note significant leadership changes, including a new Chair and a new lead portfolio manager, alongside a substantial share buyback programme totalling £115.9m.
Key Points
- Worldwide Healthcare Trust PLC (WWH) published half-year results for the six months ended 30 September 2026
- NAV per share rose from 371.0p to 403.6p; share price increased from 334.0p to 381.5p over the period
- 31,330,075 shares repurchased for treasury at a cost of £115.9m at an average discount of 7.2%; interim dividend held at 0.7p per share
- Investors should watch the discount trajectory, leverage levels at 14.9%, and the transition to new lead portfolio manager Trevor Polischuk
NAV and Share Price Performance Relative to MSCI World Health Care Benchmark
The Company's NAV per share total return of +9.3% for the six months to 30 September 2026 marginally trailed the benchmark's +9.9%, representing relative underperformance of 0.6%. However, the share price total return of +14.8% significantly exceeded the benchmark, reflecting the narrowing of the discount to NAV from 10.0% to 5.5%. The announcement identifies Eli Lilly and Natera as the top two contributors to portfolio performance, while Boston Scientific and AstraZeneca were the two principal detractors. The period included significant market volatility linked to a U.S.-Iran conflict that triggered an initial equity sell-off before markets broadly recovered.
£115.9m Share Buyback Programme and WWH Discount Control Policy
The Board repurchased 31,330,075 shares for treasury during the half year at a cost of £115.9m, at an average discount of 7.2%, reflecting its stated policy to buy back shares when the discount exceeds 6%. At the period end, 342,082,342 shares were in issue, excluding 259,582,858 shares held in treasury. From the period end to 16 November 2026, a further 7,776,867 shares were bought back at a cost of £30.0m at an average discount of 7.5%. The Company's discount of 5.5% compares favourably with the investment trust sector average of 11.8%, according to data sourced from Winterflood Investment Trusts cited in the announcement.
Portfolio Allocation Shifts: Biotechnology Overweight Trimmed, Life Science Tools Increased
The portfolio ended the half year with a 27.8% absolute weighting in biotechnology, materially above the benchmark's 11.0%, though down approximately 7.5% from the intra-period high. Pharmaceuticals weighting increased by approximately 8.5% to 42.3%, still below the benchmark's 50.5%. Life Science Tools and Diagnostics rose to 16.2% versus a benchmark weight of 10.3%, driven by conviction in liquid biopsy companies including Guardant Health, Natera, Caris Life Sciences, and CareDx. Medical Technology was cut sharply to 8.9% from 18.8% at the start of the year after anticipated recovery in surgical procedure volumes did not materialise.
New Chair William Hemmings and Lead Portfolio Manager Trevor Polischuk Take the Helm
William Hemmings succeeded Doug McCutcheon as Chair at the AGM in July 2026. Separately, Sven Borho, who was involved with the Company since its inception in 1995, stepped down as lead portfolio manager and retired from the Board on 30 October 2026. Trevor Polischuk, previously co-portfolio manager, assumed the lead role in August 2026, with Geoff Hsu appointed as co-portfolio manager simultaneously. The announcement states the Company's investment approach has not changed as a result of the transition. No performance fee was accrued as at 30 September 2026, and none can become payable within the next year.




Please wait processing your request...